RESUMEN
The investigations were carried out in 9 patients (6 women and 3 men) with rheumatoid arthritis or degenerative joint disease. All subjects were given 1000 mg nabumetone (NA) in a single daily dose at the evening, during 21 days. Before and after the therapeutic course, endoscopic examination of the upper digestive tract was carried out. On day at the begin and on the 22nd day of the NA treatment, the gastric transmucosal electric potential difference (PD) was determined, in (a) standard condition, (b) after intragastric application of 1000 mg NA, and (c) after a similar application of 1000 mg of acetylsalicylic acid (AAS). On the contrary to the effect caused by AAS (p < 0.001), NA did not result any significant change of the PD (p > 0.05), neither after a single nor after 21 day-long application (the lowest PD value before the NA therapeutic course was after a single NA dose -45.8 +/- 2.7 mV and after a single dose of AAS -40.4 +/- 2.45 mV; after the end of the NA therapy course the values were: after additional NA dose -46.7 +/- 3.5 mV and after AAS -40.5 +/- 2.7 mV) Endoscopically, any changes of the upper digestive tract mucosa which could be related to the NA therapeutic course were not detected.
Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Butanonas/farmacología , Mucosa Gástrica/efectos de los fármacos , Adulto , Antiinflamatorios no Esteroideos/uso terapéutico , Artritis Reumatoide/tratamiento farmacológico , Aspirina/farmacología , Aspirina/uso terapéutico , Butanonas/uso terapéutico , Esquema de Medicación , Femenino , Mucosa Gástrica/fisiología , Humanos , Artropatías/tratamiento farmacológico , Masculino , Persona de Mediana Edad , NabumetonaRESUMEN
The aim of the study was to find whether the type of diabetes and the duration of this disease causes any influence on gallbladder (GB) emptying, after exclusion of possible effect of obesity and a hyperglycaemia over 7 mmol/l (126 mg%) on this phenomenon. The investigations were carried out in 44 subjects with diabetes mellitus, among them 22 with type I and 22 with type II. These groups were divided according to disease duration: shorter or longer than 3 years. Two control groups (CI, CII) comprised each 20 healthy subjects. The age of CI and CII corresponded to the age of diabetes groups type I and II, respectively. All subgroups as well as the control groups were matched according to sex percentage structure, body mass index (BMI) and body surface (BS). In groups with type I and II diabetes, the number of cases with diabetic neuropathy was comparable. There was not found any significant (p > 0.05) influence of diabetes on the interdigestive GB volume, neither non-standardized nor standardized with regard to standard BS (1.73 m2). In comparison to the control groups, after a test meal, there was in all diabetic groups a statistically significant (0.001 > p < 0.05) reduction of GB emptying observed. This diminution was most expressed in the group with long-lasting type I diabetes.
Asunto(s)
Diabetes Mellitus Tipo 1/fisiopatología , Diabetes Mellitus Tipo 2/fisiopatología , Ingestión de Alimentos/fisiología , Vaciamiento Vesicular/fisiología , Adulto , Estudios de Casos y Controles , Femenino , Vesícula Biliar/fisiopatología , Humanos , Masculino , Persona de Mediana EdadRESUMEN
The aim of the study was to investigate whether oral application of misoprostol (MI), which is an analogue of prostaglandin E1, does change the secretion of insulin and the blood glucose level. The investigations were carried out in 15 subjects, aged 21-40 yrs, with a gastric or duodenal ulcer and without any disturbances of the digestive tract motility. In 7 of them (group A), without stated diabetes a single oral dose of 400 mg MI versus placebo (PL) and 15 min later 75 g glucose p.o., was applied in randomized order, on different days, in fasting state. In 8 subjects with mild diabetes type II (gr B) MI versus PL and after 15 min. i.v. 1.0 mg glucagon was similarly administered. In both groups the concentrations of glucose and C-peptide in blood were determined. In comparison to PL, the application of MI did not cause any statistically significant differences of C-peptide in serum and blood glucose levels neither before and after oral glucose loading nor after i.v. administration of glucagon. Statistically not significant were also the differences in AUC (p > 0.05).